^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FCGR2B (Fc Fragment Of IgG Receptor IIb)

    i
    Other names: FCGR2B, Fc Fragment Of IgG Receptor IIb, Low Affinity Immunoglobulin Gamma Fc Region Receptor II-B, Fc Fragment Of IgG Low Affinity IIb Receptor For (CD32), Fc Fragment Of IgG Low Affinity IIb Receptor (CD32), Fc Gamma Receptor IIb, IgG Fc Receptor II-B, Fc-Gamma RII-B, Fc-Gamma-RIIb, FcRII-B, CDw32, IGFR2, FCG2, CD32, Low Affinity Immunoglobulin Gamma Fc Region Receptor II-C, Fc Fragment Of IgG Low Affinity II Receptor For (CD32), IgG Fc Receptor II-C, Fc-Gamma RII-C, Fc Gamma RIIb, Fc-Gamma-RIIc, CD32 Antigen, FcRII-C, FCGR2C, CD32B, FCGR2
    25d
    Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma. (PubMed, Front Med (Lausanne))
    CD320, SLC44A1, and TNFRSF13B are promising, clinically relevant targets for CAR T-cell therapy in MM. Their stage-specific expression and prognostic significance support their potential to enhance existing immunotherapeutic strategies.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule) • SDC1 (Syndecan 1) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • CD59 (CD59 Molecule) • SLAMF7 (SLAM Family Member 7) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    26d
    Activation of FCGR2A enhances the antitumor efficacy of hPSC-derived CAR-M. (PubMed, Front Cell Dev Biol)
    Furthermore, polarization of CAR-Ms into a proinflammatory state significantly enhanced tumor-killing efficacy, particularly in FCGR2A CAR-Ms. These findings highlight the potential of FCGR2A as an optimal signaling domain for CAR-M design and underscore the therapeutic promise of proinflammatory polarized CAR-Ms in solid tumor immunotherapy.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • FCGR1A (Fc Fragment Of IgG Receptor Ia) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    HER-2 positive • HER-2 expression
    1m
    Multi-Omics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer. (PubMed, Mol Cell Proteomics)
    Notably, Fc fragment of IgG receptor IIa (FCGR2A, or CD32) was identified as a promising biomarker for ATC, implicating a functional link between immune evasion and tumor aggressiveness. Our findings provide a comprehensive molecular and immunological characterization of thyroid cancer subtypes, offering novel insights into the pathogenesis of ATC and PDTC, and identifying potential targets for diagnosis and precision therapy.
    Journal
    |
    FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    2ms
    The influence of CXCL9 on M2 macrophages in lung cancer development. (PubMed, Transl Cancer Res)
    Moreover, CXCL9 inhibited the activation of the ERK and AKT signaling pathways, further inhibiting tumor cell proliferation and invasion. CXCL9 inhibits the proliferation, migration, metastasis and invasion of lung cancer cells by inhibiting M2 macrophage polarization and function, indicating that CXCL9 may serve as a potential therapeutic target for lung cancer.
    Journal
    |
    CXCL9 (Chemokine (C-X-C motif) ligand 9) • MMP2 (Matrix metallopeptidase 2) • VEGFC (Vascular Endothelial Growth Factor C) • FCGR2A (Fc fragment of IgG receptor IIa) • MMP9 (Matrix metallopeptidase 9) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • MRC1 (Mannose Receptor C-Type 1)
    2ms
    Exploratory Immunohistochemical Profiling of FOXP3, PD-1 and CD32B in Resectable Lung Adenocarcinoma. (PubMed, Cancers (Basel))
    In this hypothesis-generating pilot, an immunosuppressive tumor microenvironment, indexed by higher FOXP3 (relative to CD8) and higher CD32B (relative to CD19), portends earlier recurrence after surgery. These results support external validation in larger, stage-balanced cohorts and motivate incorporation of quantitative IHC ratios into postoperative risk stratification.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • FOXP3 (Forkhead Box P3) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    3ms
    Spatiotemporal profiling of endocytic regulators in the immunosuppressive TAM microenvironment of glioma. (PubMed, Brain Res)
    Immunohistochemistry and Western blot analyses further validated their elevated protein expression in high-grade glioma tissues. Collectively, this spatial multi-omic framework delineates endocytosis-associated immune remodeling in glioma and identifies FCGR2B, CLEC7A, and LYAR as potential biomarkers and therapeutic targets for disrupting immunosuppressive niches.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • CLEC7A (C-Type Lectin Domain Containing 7A) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    3ms
    Genomic characterization of host gene alterations in Theileria annulata-transformed leukocytes. (PubMed, Commun Biol)
    Functional studies revealed that inhibition of the mutated oncogene ROS1 using crizotinib induces death in infected leukocytes, confirming its role in transformation...Our findings provide new insights into how T. annulata reprograms host cells through genomic instability and mutations, identifying ROS1 and TP53 as critical targets for therapeutic intervention. This work advances understanding of parasite-induced oncogenic transformation and offers pathways for future research.
    Journal
    |
    TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BAP1 (BRCA1 Associated Protein 1) • KMT2C (Lysine Methyltransferase 2C) • NOTCH2 (Notch 2) • FLT4 (Fms-related tyrosine kinase 4) • BARD1 (BRCA1 Associated RING Domain 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) • DAXX (Death-domain associated protein) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
    |
    TP53 mutation
    |
    Xalkori (crizotinib)
    4ms
    IgG4-related disease in the Japanese population: a whole-genome sequencing study. (PubMed, Lancet Rheumatol)
    C4 copy number variation, in addition to HLA and FCGR2B, was found to be a distinct genetic factor associated with IgG4-related disease susceptibility, illustrating the complex polygenic nature of the disease. Furthermore, the identification of PTCH1 and the long non-coding RNA LOC102724227 as Mikulicz's disease-specific susceptibility loci suggests that genetic heterogeneity might underlie the clinical diversity of IgG4-related disease, particularly with respect to the affected organs.
    Journal
    |
    PTCH1 (Patched 1) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    4ms
    Identification and Validation of a Macrophage Phagocytosis-Related Gene Signature for Prognostic Prediction in Colorectal Cancer (CRC). (PubMed, Curr Issues Mol Biol)
    Single-cell RNA sequencing analysis demonstrated a decrease in SPHK1 and FCGR2B, while VSIG4 and FPR2 progressively increased during macrophage differentiation. These findings provide a potential framework for targeted therapy.
    Journal • Gene Signature • IO biomarker
    |
    FCGR2B (Fc Fragment Of IgG Receptor IIb) • FPR2 (Formyl Peptide Receptor 2) • SPHK1 (Sphingosine Kinase 1)
    4ms
    The S1P/S1P1 Signaling Axis Plays Regulatory Functions in the Crosstalk Between Brain-Metastasizing Melanoma Cells and Microglia. (PubMed, Cancers (Basel))
    S1P1 contributes to the immunosuppressive phenotype of microglia. Inhibiting the S1P/S1P1 axis impairs viability and crosstalk between melanoma cells and tumor-activated microglia, offering a potential therapeutic strategy for melanoma brain metastases.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6) • CD163 (CD163 Molecule) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit) • S1PR1 (Sphingosine-1-Phosphate Receptor 1) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    Zelboraf (vemurafenib)
    5ms
    Myeloid cell recruitment and activation through systemic and mucosae-directed cytokine therapy. (PubMed, Immunol Cell Biol)
    Overall, our findings delineate the kinetics of systemic and mucosal myeloid cell expansion, activation and trafficking achieved by subQ GM-CSF administration in RM. These findings will inform the use of GM-CSF as an adjuvant in clinical applications where myeloid cell mobilization is advantageous.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CSF2 (Colony stimulating factor 2) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • IL1R1 (Interleukin 1 receptor, type I)
    5ms
    Engineering an Fc-inert feline IgG1 by targeted mutations: Application to anti-PD-1 antibody development. (PubMed, Vet Immunol Immunopathol)
    Despite these modifications, the mutated antibodies effectively restored IFN-γ production, which had been suppressed by PD-1/PD-L1 signaling in stimulated lymphocytes, to levels comparable to those of the original antibody. These findings reveal that the engineered antibodies have potential for future clinical applications in feline oncology.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb)